Products
Platform
Research
Market
Learn
Compare ICICI Prudential Nifty Pharma Index Fund vs DSP Healthcare Fund
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Fund Details
Risk | Very High | Very High |
Rating | - | 4.0 |
Min SIP Amount | ₹1000 | ₹100 |
Expense Ratio | 0.98 | 1.91 |
NAV | ₹17.33 | ₹40.32 |
Fund Started | 25 Nov 2022 | 12 Nov 2018 |
Fund Size | ₹91.49 Cr | ₹3056.90 Cr |
Exit Load | - | Exit load of 0.50% if redeemed within 1 month. |
Risk
Very High
Very High
Rating
-
4.0
Min SIP Amount
₹1000
₹100
Expense Ratio
0.98
1.91
NAV
₹17.33
₹40.32
Fund Started
25 Nov 2022
12 Nov 2018
Fund Size
₹91.49 Cr
₹3056.90 Cr
Exit Load
-
Exit load of 0.50% if redeemed within 1 month.
Returns
1 Year | 4.37% | 7.88% |
3 Year | - | 24.97% |
5 Year | - | 21.24% |
1 Year
4.37%
7.88%
3 Year
-
24.97%
5 Year
-
21.24%
Holding Analysis
Equity | 99.97% | 98.31% |
Cash | 0.03% | 1.69% |
Equity
99.97%
98.31%
Cash
0.03%
1.69%
Top Holdings
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 22.86% |
Divi's Laboratories Ltd. | 10.94% |
Cipla Ltd. | 10.71% |
Dr. Reddy's Laboratories Ltd. | 9.88% |
Lupin Ltd. | 5.93% |
Torrent Pharmaceuticals Ltd. | 4.51% |
Aurobindo Pharma Ltd. | 4.01% |
Laurus Labs Ltd. | 3.59% |
Alkem Laboratories Ltd. | 3.36% |
Glenmark Pharmaceuticals Ltd. | 3.34% |
Name | Assets |
|---|---|
Cipla Ltd. | 8.82% |
Sun Pharmaceutical Industries Ltd. | 8.42% |
Cohance Lifesciences Ltd. | 7.88% |
Ipca Laboratories Ltd. | 7.71% |
Gland Pharma Ltd. | 5.52% |
Laurus Labs Ltd. | 5.26% |
Alembic Pharmaceuticals Ltd. | 4.85% |
Apollo Hospitals Enterprise Ltd. | 4.61% |
Globus Medical Inc | 4.44% |
Sai Life Sciences Ltd. | 4.31% |
Fund Manager
Name | Kayzad Eghlim | Jay Kothari |
Start Date | 03 Dec 2021 | 16 Mar 2018 |
Name
Kayzad Eghlim
Jay Kothari
Start Date
03 Dec 2021
16 Mar 2018
About Fund
Description | The Scheme seeks to invest in companies whose securities are included in Nifty Pharma Index and subject to tracking errors, to endeavor to achieve the returns of the above index. This would be done by investing in all the stocks comprising the Nifty Pharma Index in the same weightage that they represent in Nifty Pharma Index | The scheme seeks to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies. |
Launch Date | 25 Nov 2022 | 12 Nov 2018 |
Description
The Scheme seeks to invest in companies whose securities are included in Nifty Pharma Index and subject to tracking errors, to endeavor to achieve the returns of the above index. This would be done by investing in all the stocks comprising the Nifty Pharma Index in the same weightage that they represent in Nifty Pharma Index
The scheme seeks to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies.
Launch Date
25 Nov 2022
12 Nov 2018
